Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of empagliflozin 25 mg in healthy Thai volunteers
TCTR20230719003Phase 0Completed
- Sponsor
- MacroPhar
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 0, randomised, open-label trial of empagliflozin (2 arms), sponsored by MacroPhar. Primary endpoint: Pharmacokinetic parameters under fasting conditions. Started Dec 2023; status: completed.
02
Drugs
empagliflozin
Beyond the preview
Go deeper on TCTR20230719003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230719003.